IN June, Novo Nordisk faced serious cybersecurity threats as two separate groups claimed to have stolen data, including intellectual property. One group demanded $25 million and the other $50 million for the stolen information. Following a lack of payment, both groups leaked the data online. Despite these breaches, Novo Nordisk's stock price remained stable, closing at €38.90 with a weekly increase of 2.29%.
Investors seemed to prioritize the company's successful launch of an oral version of Wegovy and a significant research initiative over the risks associated with the breaches. The company did not respond to inquiries about the breach or its potential impact on investors.